Over-the-counter use of short-acting beta-2 agonists: a systematic review

Figures & data

Table 1 Databases and keywords used in search strategies

Fig. 1 A flow diagram for study selection

Table 2 Characteristics of the studies

Fig. 2 The social and cognitive theory framework diagram

Alzaabi A, Al Busaidi N, Pradhan R, Shandy F, Ibrahim N, Ashtar M, et al.Over-prescription of short-acting β2-agonists and asthma management in the Gulf region: a multicountry observational studyAsthma Res Pract202283 10.1186/s40733-022-00085-5 35799290 9260980

 PubMedGoogle Scholar

Azzi EA, Kritikos V, Peters MJ, Price DB, Srour P, Cvetkovski B, et al.Understanding reliever overuse in patients purchasing over-the-counter short-acting beta 2 agonists: an Australian community pharmacy-based surveyBMJ Open2019 10.1136/bmjopen-2019-028995 31412998 6701672

 PubMed Web of Science ®Google Scholar

Bateman ED, Price DB, Wang H-C, Khattab A, Schonffeldt P, Catanzariti A, et al.Short-acting β 2 -agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III studyEur Respir J2021 10.1183/13993003.01402-2021 34667060

 PubMed Web of Science ®Google Scholar

Yorgancıoğlu A, Aksu K, Naycı SA, Ediger D, Mungan D, Gül U, et al.Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA IIIBMC Pulm Med202222216 1:CAS:528:DC%2BB38XhsVKhtrrM 10.1186/s12890-022-02008-9 35655251 9161536

 PubMed Web of Science ®Google Scholar

Al-Jahdali H, Wali S, Albanna A, Al Harbi A, Allehebi R, Arwadi A, et al.Overprescription of short-acting β2 -agonists among patients with asthma in Saudi Arabia: results from the SABINA III cohort studyClin Respir J2022 10.1111/crj.13553 36279888 9716708

 PubMed Web of Science ®Google Scholar

Douglass JA, Goeman DP, McCarthy EA, Sawyer SM, Aroni RA, Stewart K, et al.Over-the-counter β2-agonist purchase versus script: a cross-sectional studyRespir Med2012106223229 10.1016/j.rmed.2011.09.012 22040532

 PubMed Web of Science ®Google Scholar

Bao W, Zhang Y, Hang J, Guo Y, Tang W, Yun C, et al.Short-acting beta-2 agonist prescription patterns and clinical outcomes in Chinese patients with asthma: an observational study in mainland China for the SABINA programmeTher Adv Respir Dis20221617534666221115054 1:CAS:528:DC%2BB38Xjt1Whs7nM 10.1177/17534666221115054 36065527 9449520

 PubMed Web of Science ®Google Scholar

Azzi E, Kritikos V, Peters M, Price D, Cvetkovski B, Alphonse PS, et al.Perceptions, attitudes, and behaviors of short-acting beta2 agonist users: an Australian cross-sectional community pharmacy-based studyJ Asthma202259178188 1:CAS:528:DC%2BB3cXit1Ggtb%2FO 10.1080/02770903.2020.1841223 33086885

 PubMed Web of Science ®Google Scholar

Montero-Arias F, Garcia JCH, Gallego MP, Antila MA, Schonffeldt P, Mattarucco WJ, et al.Over-prescription of short-acting β2-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III studyJ Asthma2022 10.1080/02770903.2022.2082305 35670783

 PubMed Web of Science ®Google Scholar

Avdeev S, Voznesenskiy N, Boldina M, Ignatova G, Kostina N, Kulbaisov A, et al.SABA overuse in Russia—burden and possible causes: an analysis of the Russian population in the SABINA III (SABA use IN Asthma) studyJ Asthma Allergy2022 10.2147/JAA.S350393 35368426 8965337

 PubMed Web of Science ®Google Scholar

Price D, Hancock K, Doan J, Taher SW, Muhwa CJ, Farouk H, et al.Short-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohortNPJ Prim Care Respir Med20223237 10.1038/s41533-022-00295-7 36175556 9522811

 PubMed Web of Science ®Google Scholar

Reddel HK, Ampon RD, Sawyer SM, Peters MJRisks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population surveyBMJ Open20177 10.1136/bmjopen-2017-016688 28947448 5623555

 PubMed Web of Science ®Google Scholar

Di Marco F, D’Amato M, Lombardo FP, Micheletto C, Heiman F, Pegoraro V, et al.The burden of short-acting β2-agonist use in asthma: is there an Italian case? An update from SABINA programAdv Ther2021 10.1007/s12325-021-01772-0 34043208 8280008

 PubMed Web of Science ®Google Scholar

Campbell DA, Ruffin RE, Wilson DJD, Farmer EA, Wakefield MA, Chittleborough CROver-the-counter purchase of inhaled beta-2 agonists: a qualitative study of asthma patientsHealth Promot J Austr2000103842

 Google Scholar

Shen S-Y, Chen C-W, Liu T-C, Wang C-Y, Chiu M-H, Chen Y-J, et al.SABA prescriptions and asthma management practices in patients treated by specialists in Taiwan: results from the SABINA III studyJ Formos Med Assoc202212125272537 10.1016/j.jfma.2022.05.014 35718640

 PubMed Web of Science ®Google Scholar

Pedrozo-Pupo JC, Gallego MCP, de Álvarez IJB, Raad RAJ, Pinilla ACC, Londoño HR, et al.A cross-sectional study on prescription patterns of short-acting β2-agonists in patients with asthma: results from the SABINA III Colombia cohortJ Asthma Allergy20221511671178 10.2147/JAA.S365009 36051434 9427209

 PubMed Web of Science ®Google Scholar

Modi M, Mody K, Jhawar P, Sharma L, Padukudru Anand M, Gowda G, et al.Short-acting β2-agonists over-prescription in patients with asthma: an Indian subset analysis of international SABINA III studyJ Asthma2022 10.1080/02770903.2022.2147079 36519934

 PubMed Web of Science ®Google Scholar

Khattab A, Madkour A, Ambaram A, Smith C, Muhwa CJ, Mecha JO, et al.Over-prescription of short-acting β2-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III studyCurr Med Res Opin2022 10.1080/03007995.2022.2100649 36031882

 PubMed Web of Science ®Google Scholar

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.